Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved

MeSH terms

• Aged
• Androgen Antagonists / adverse effects*
• Androgen Antagonists / therapeutic use
• Cardiovascular Diseases / epidemiology*
• Cardiovascular Diseases / etiology
• Humans
• Incidence
• Male
• Prostatic Neoplasms* / complications
• Prostatic Neoplasms* / drug therapy
• Prostatic Neoplasms* / epidemiology
• Risk Assessment*
• Risk Factors
• Survival Rate / trends
• United Kingdom / epidemiology